26 results about "Adenomyosis" patented technology

The present invention relates to the use of compounds of formula (I) as RAS inhibitors and as a medicament, in particular for use in treating proliferative disorders, inflammatory diseases and / or genetic disorders. The present invention relates further to a pharmaceutical composition comprising the compounds of formula (I). Moreover, the present invention relates to a method of inhibiting growth, proliferation or metastasis of cancer cells in a subject in need thereof, in particular which may encompass subsets of patients defined by their mutational status of the RAS oncogene or patients who might have developed resistance to the standard of care or treatment with RAS mutation specific inhibitors. The present invention also relates to a method of inhibiting RAS molecules in treating genetic disorders like RASopathies or inflammatory disorders like Adenomyosis where KRAS gene is mutationally activated. In addition, the present invention relates to a method of inhibiting proliferation and or secretion of factors from a cell population sensitive towards inhibiting RAS activation in vitro, in particular sensitive towards inhibiting KRAS. HRAS and NRAS activation in vitro. Furthermore, the present invention relates to a kit containing a formulation comprising a pharmaceutical composition comprising a compound of formula (I).

The utility model relates to a kind of human adenomyosis ectopic epithelium and stromal cell separation culture devices. The device includes L-shaped base, fixed tube, centrifugal tube, filter separation component. Two centrifugal tubes are used to collect stromal cell and epithelial cell respectively, and the top end of centrifugal tube is connected with top cover. Filter separation component includes mounting ring, locating ring, flexible filter screen, annular frame and positioning mechanism. Mounting ring is horizontally arranged, locating ring is peripherally arranged on mounting ring, and locating ring is adapted to the top end of centrifugal tube, filter screen is arranged at the bottom of mounting ring, the bottom of annular frame is connected with the bottom surface of flexible filter screen, gap is provided between the top of annular frame and mounting ring, and annular frame is limited by positioning mechanism. Compared with prior art, the utility model can simplify the separation process of human adenomyosis ectopic epithelium and stromal cell, reduce cleaning work, and is suitable for laboratory culture operation.

The present invention relates to an integrated diagnostic system for deep endometriosis and / or adenomyosis, comprising three interconnected platforms and a method for analysing images generated by algorithms. The first platform combines patient medical history data with transvaginal ultrasound and / or pelvic magnetic resonance images, using algorithms to generate clear and detailed images of lesions. The method for analysing these images includes pre-processing, merging of clinical data and images, lesion identification, and comparison with a clinical database, resulting in a visual and descriptive analysis of the lesions, facilitating early and assertive diagnosis. The second platform is a communication network among specialist physicians, who perform a second reading of the images and issue a validated final report. The third platform is educational, offering personalised training and mentoring for imaging physicians using the images generated by the first platform to improve their diagnostic skills. The system reduces diagnostic time, increases accuracy, and contributes to the continuous professional development of physicians involved in the management of deep endometriosis and / or adenomyosis.

This invention relates to methods for treating endometriosis and providing effective contraception. Specifically, it relates to drospirenone in methods for treating endometriosis, endometriosis-associated pelvic pain (EAPP), and / or dysmenorrhea, the method comprising administering drospirenone in a biphasic regimen. The invention also relates to the use of drospirenone administered in such a biphasic regimen as a contraceptive and for inducing amenorrhea, and to pharmaceutical compositions and devices comprising drospirenone administered in such a biphasic regimen.

The present invention relates to the use of compounds of formula (I) as RAS inhibitors and as a medicament, in particular for use in treating proliferative disorders, inflammatory diseases and / or genetic disorders. The present invention relates further to a pharmaceutical composition comprising the compounds of formula (I). Moreover, the present invention relates to a method of inhibiting growth, proliferation or metastasis of cancer cells in a subject in need thereof, in particular which may encompass subsets of patients defined by their mutational status of the RAS oncogene or patients who might have developed resistance to the standard of care or treatment with RAS mutation specific inhibitors. The present invention also relates to a method of inhibiting RAS molecules in treating genetic disorders like RASopathies or inflammatory disorders like Adenomyosis where KRAS gene is mutationally activated. In addition, the present invention relates to a method of inhibiting proliferation and / or secretion of factors from a cell population sensitive towards inhibiting RAS activation in vitro, in particular sensitive towards inhibiting KRAS, HRAS and NRAS activation in vitro. Furthermore, the present invention relates to a kit containing a formulation comprising a pharmaceutical composition comprising a compound of formula (I).

The invention relates to the field of absorbable suture lines, in particular to a degradable drug-loaded suture line and a preparation method and application thereof. The invention provides a degradable drug-loaded suture which is composed of a dispersed phase and a continuous phase, and a uniform wrapping layer is formed on the surface of the dispersed phase by using the continuous phase; the dispersion phase comprises a degradable polymer, an organic solvent and a loaded drug; the continuous phase comprises a surfactant and an alcohol solution. The degradable drug-loaded suture line prepared by the invention is used for preparing products for suturing skin and deep tissue after adenomyosis surgery, has good biocompatibility, can avoid suture removal, stably releases drugs at the sutured part, and reduces side effects caused by repeated medication.

The invention relates to the technical field of biological medicine, and provides cascade response type nanoparticles for adenomyosis and a preparation method thereof. The core of the system is nanoparticles constructed based on a carrier PLGA-(S-S-PPS) 2, and the disulfide bond of the carrier can be specifically broken and disintegrated in high-concentration H2O2 of a focus. The nanoparticles are loaded with a pH responsive fluorescent-ketal-berberine prodrug, ketal bonds are hydrolyzed in an acidic microenvironment, and berberine is released to realize fluorescence visualization. Hyaluronidase is encapsulated in the nanoparticles and is used for degrading a hyaluronic acid matrix. The surface modified RGD peptide can be specifically combined with integrin alpha v beta 3 to realize active targeting. The synergistic action mechanism of the system is as follows: RGD-mediated targeted accumulation, the carrier disintegrates and releases the content under H2O2, hyaluronidase degrades the matrix to enhance permeation, the prodrug releases berberine in an acid environment, and cell proliferation is synergistically inhibited and angiogenesis is reduced. Experiments prove that the hydrogel has good ROS / pH / enzyme responsiveness, fluorescence visualization, targeted accumulation, high drug loading rate (18.7%) and biological safety.

In an illustrative embodiment, methods and systems for treating fertility conditions in women diagnosed with polycystic ovary syndrome (PCOS), endometriosis, and / or adenomyosis using electrical neurostimulation include delivering neurostimulation therapy via electrical or mechanical stimulation elements, the neurostimulation therapy including applying first neurostimulation pulses using electrical neurostimulation or mechanical neurostimulation at one or more first regions of skin of the subject to directly and / or indirectly activate a nucleus tractus solitary (NTS) and / or a trigeminal cervical complex (TCC) to activate anti-inflammatory pathways, and applying second neurostimulation pulses using electrical neurostimulation or mechanical neurostimulation at one or more second regions of skin of the subject to directly and / or indirectly activate vagal neural fibers and / or trigeminal neural fibers, wherein the neurostimulation pulses are configured to increase a parasympathetic / sympathetic (P / S) ratio.

The present invention relates to the use of compounds of formula (I) as RAS inhibitors and as a medicament, in particular for use in treating proliferative disorders, inflammatory diseases and / or genetic disorders. The present invention relates further to a pharmaceutical composition comprising the compounds of formula (I). Moreover, the present invention relates to a method of inhibiting growth, proliferation or metastasis of cancer cells in a subject in need thereof, in particular which may encompass subsets of patients defined by their mutational status of the RAS oncogene or patients who might have developed resistance to the standard of care or treatment with RAS mutation specific inhibitors. The present invention also relates to a method of inhibiting RAS molecules in treating genetic disorders like RASopathies or inflammatory disorders like Adenomyosis where KRAS gene is mutationally activated. In addition, the present invention relates to a method of inhibiting proliferation and / or secretion of factors from a cell population sensitive towards inhibiting RAS activation in vitro, in particular sensitive towards inhibiting KRAS, HRAS and NRAS activation in vitro. Furthermore, the present invention relates to a kit containing a formulation comprising a pharmaceutical composition comprising a compound of formula (I).

The invention discloses a uterine cavity built-in cooling system for adenomyosis HIFU treatment, the uterine cavity built-in cooling system comprises an infusion bag, a balloon and a gas injection needle tube, the lower side of the infusion bag is provided with rubber ports, the lower ends of the group of rubber ports are provided with a medical three-way valve, and the lower end of the medical three-way valve is communicated with a water inlet pipe; the lower end of the water inlet pipe is communicated with a balloon, and the outer side of the balloon is communicated with a water outlet pipe; and a gas injection needle tube is inserted into the other set of rubber ports, the outer side of the lower end of the gas injection needle tube communicates with a gas inlet tube, and a pressurizing device is installed at the lower end of the gas inlet tube. The lower end of the water inlet pipe is communicated with the balloon, so that low-temperature water in the infusion bag is continuously injected into the balloon at a low speed through the medical three-way valve and the water inlet pipe to fill the balloon, and then the balloon is uniformly spread and attached to the uterine wall to cool the body, and a low-temperature state can be maintained.

The present invention relates to the use of compounds of formula (I) as RAS inhibitors and as a medicament, in particular for use in treating proliferative disorders inflammatory diseases and / or genetic disorders. The present invention relates further to a pharmaceutical composition comprising the compounds of formula (I). Moreover, the present invention relates to a method of inhibiting growth, proliferation or metastasis of cancer cells in a subject in need thereof, in particular which may encompass subsets of patients defined by their mutational status of the RAS oncogene or patients who might have developed resistance to the standard of care or treatment with RAS mutation specific inhibitors. The present invention also relates to a method of inhibiting RAS molecules in treating genetic disorders like RASopathies or inflammatory disorders like Adenomyosis where KRAS gene is mutationally activated. In addition, the present invention relates to a method of inhibiting proliferation and or secretion of factors from a cell population sensitive towards inhibiting RAS activation in vitro, in particular sensitive towards inhibiting KRAS, HRAS and NRAS activation in vitro. Furthermore, the present invention relates to a kit containing a formulation comprising a pharmaceutical composition comprising a compound of formula (I).

The disclosure provides methods and devices for the treating or preventing a benign uterine disorder in a female mammalian subject. The methods comprise administering a non-steroidal angiogenesis inhibitor. Such methods and devices are particularly useful for treating women suffering from adenomyosis and related symptoms.

This invention discloses a medical endometriosis surgery guide, belonging to the field of medical device technology. It includes a base rod, an insertion rod, and a base. The insertion rod is connected to the bottom end of the outer wall of the base rod, and the base is connected to the top end of the outer wall of the base rod. The medical endometriosis surgery guide disclosed in this invention, through modular assembly and threaded connection design, allows for independent and quick replacement of components without the need to discard the entire instrument. The insertion rod, with its anti-slip texture, prevents the instrument from slipping during critical steps. A press-to-unlock, rotation-to-adjust, and spring-reset locking mechanism allows for quick and flexible angle adjustment during surgery, ensuring a secure lock after rotation without the risk of loosening. Furthermore, the adjustable angle is combined with the physiological curvature of the rectum, reducing the risk of tissue traction or puncture injury caused by forced instrument insertion.

The present invention relates to dosing regimens for GnRH receptor antagonists, and, in particular, dosing regimens for 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino)-butyric acid (Compound A) or a pharmaceutically acceptable salt thereof, in subjects suffering from, for example, endometriosis, adenomyosis, polycystic ovary syndrome (PCOS), or uterine fibroids, to minimize changes in bone mineral density associated with such GnRH receptor antagonists.

The application belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating adenomyosis and application thereof. The traditional Chinese medicine composition is prepared from raw medicinal materials in the following mass fractions: 20-45 parts of Astragalus membranaceus, 10-15 parts of Ramulus Cinnamomi, 10-15 parts of Angelica sinensis, 10-15 parts of Fried Semen Persicae, 6-9 parts of Rhei Radix et Rhizoma with liquor, 10-12 parts of Poria cocos, 6-9 parts of Eupolyphaga, 6-9 parts of Yunnan giant Himalayan lily, and 3-6 parts of Panax notoginseng powder. The clinical research results prove that the traditional Chinese medicine composition can effectively treat adenomyosis of yang deficiency and blood stasis type, improve symptoms such as dysmenorrhea, chronic pelvic pain, menorrhagia, prolonged menstrual period and the like of patients, and improve hemoglobin level, while avoiding obvious adverse reactions, and therefore has good practical application value.

Control tissues and different lesions of either adenomyosis or endometriosis were exposed in vitro during 24 hours either to vehicle (DMSO) or different doses of BYL719 or ST420, a PIK3CA inhibitor. Inventors observed that lesions treated with DMSO had a higher recruitment of the PIK3CA pathway compared to healthy endometrium. Importantly, both inhibitors were able to shut down the phosphorylation of AKT. They concluded that PIK3CA inhibition is a good therapeutic target for patients with endometriosis and adenomyosis. They also investigated the role of the PIK3CA pathway in myoma, another benign uterine condition. They observed that either alpelisib or ST420 were able to inhibit the pathway in myoma. They concluded that myoma demonstrate PIK3CA / AKT pathway activation with somatic mutation and are accessible to targeted treatment. Accordingly, the invention relates to method for treating uterine disease in a subject in need thereof comprising a step of administrating the subject with a therapeutically effective amount of PIK3CA inhibitor such as compound of formula (I), or a deuterated or tritiated form of the compound of formula (I), BYL719.

Provided herein is a targeting molecule, wherein the targeting molecule binds to a surface molecule on an endometrial endothelial cell (EEC) in which expression of the surface molecule is upregulated.

The application provides application of hydroxysafflor yellow A in preparation of medicines for preventing, treating and / or relieving endometriosis, and belongs to the technical field of biological medicines. The application provides application of hydroxysafflor yellow A in preparation of medicines for preventing, treating and / or relieving endometriosis. Hydroxysafflor yellow A can inhibit migration and / or diffusion of endometriosis cyst, inhibit migration, invasion and abnormal planting of endometrial tissue and / or endometriosis cells outside the uterine cavity, relieve inflammatory reaction caused by endometriosis, and effectively curb lesion invasion and disease progression of endometriosis. As a main active component of safflower, hydroxysafflor yellow A provides a new direction for manufacturing new medicines for treating endometriosis by using safflower.

This invention relates to the field of ultrasound imaging diagnostic technology, and discloses a method and system for diagnosing adenomyosis based on multi-parameter ultrasound imaging of the cervix. The method utilizes a transvaginal probe to acquire two-dimensional grayscale, shear wave elasticity, and ultra-micro blood flow images of the cervix. An anatomical coordinate system is established based on the longitudinal axis of the cervical canal in the grayscale image, and multiple independent quantitative analysis sub-regions covering the internal os and mid-segment of the cervix are identified as measurement target areas within the cervical parenchyma. Young's modulus, reflecting tissue stiffness, and resistance index, reflecting microcirculatory resistance, are extracted from the elasticity and blood flow images, respectively. The extracted parameters are input into a multivariate logistic regression diagnostic model, and the probability value of disease risk is calculated based on weighted coefficients, outputting a classification conclusion. This invention overcomes the limitations of morphological diagnosis through a standardized target area localization strategy and multi-modal parameter joint modeling, achieving objective quantitative diagnosis of adenomyosis and improving the accuracy and repeatability of detection.

The application provides a use of STRA6 and miR-1249-5p in preparation of a product for diagnosing adenomyosis, and relates to the technical field of biology.The inventors have found that vascular smooth muscle cell membranes of patients with adenomyosis have high specific expression of retinoic acid transport associated protein STRA6, and further research has found that the expression of STRA6 is mediated by miR-1249-5p, under the action of estrogen, miR-1249-5p can directly target the 3'-UTR of the STRA6 gene to regulate intracellular retinoic acid metabolism, affect vascular smooth muscle function and participate in the occurrence of adenomyosis.Therefore, the expression amount of the STRA6 gene and miR-1249-5p can realize the diagnosis of adenomyosis.

The utility model discloses a kind of cutting knives for adenomyosis uterine conservation U surgery, it is related to the technical field of medical devices, the utility model aims at solving the problem that healthy cells are easily damaged in adjusting blade tip position during uterine conservation U surgery process, the utility model includes cutter barrel, the bottom end of the cutter barrel is open, cutting knife body is coaxially sleeved in the cutter barrel, two vertical grooves are formed in the side wall of the cutter barrel, the top of two vertical grooves is communicated by ring groove, the outer wall of cutting knife body is connected with sliding cap by sliding block, the sliding block is slidingly connected in the vertical groove, and the sliding cap is arranged outside the cutter barrel.

The invention relates to the field of absorbable drug-loaded microspheres, in particular to a degradable drug-loaded microsphere as well as a preparation method and application thereof. The invention provides a degradable drug-loaded microsphere and a preparation method thereof, the degradable drug-loaded microsphere is composed of a dispersed phase and a continuous phase, and is prepared based on a microfluidic technology by using shear force and interfacial tension generated by incompatibility between the continuous phase and the dispersed phase; the dispersion phase comprises a degradable polymer, an organic solvent and a loaded drug; the continuous phase includes a surfactant and water. The prepared degradable drug-loaded microspheres are used in drugs for treating adenomyosis, after the degradable drug-loaded microspheres are injected into the focus of adenomyosis, microcarriers in the degradable drug-loaded microspheres are naturally degraded, the drugs are slowly released in vivo, repeated injection is avoided, the blood concentration in vivo is effectively reduced, and the drug-loaded microspheres can be used for treating the adenomyosis. The adverse reaction caused by hormone treatment is reduced.

The present invention relates to the use of compounds of formula (I) as RAS inhibitors and as a medicament, in particular for use in treating proliferative disorders, inflammatory diseases and / or genetic disorders and / or genetic disorders. The present invention relates further to a pharmaceutical composition comprising the compounds of formula (I). Moreover, the present invention relates to a method of inhibiting growth, proliferation or metastasis of cancer cells in a subject in need thereof, in particular which may encompass subsets of patients defined by their mutational status of the RAS oncogene or patients who might have developed resistance to the standard of care or treatment with RAS mutation specific inhibitors. The present invention also relates to a method of inhibiting RAS molecules in treating genetic disorders like RASopathies or inflammatory disorders like Adenomyosis where KRAS gene is mutationally activated. In addition, the present invention relates to a method of inhibiting proliferation and / or secretion of factors from a cell population sensitive towards inhibiting RAS activation in vitro, in particular sensitive towards inhibiting KRAS, HRAS and NRAS activation in vitro. Furthermore, the present invention relates to a kit containing a formulation comprising a pharmaceutical composition comprising a compound of formula (I).

This invention relates to an automatic classification method and system for adenomyosis based on multiplanar MRI images, belonging to the field of adenomyosis classification technology, and solving the problem of inaccurate classification in existing technologies. The method includes the following steps: segmenting multiplanar MRI images of different individuals using multiple trained segmentation models to extract the multiplanar uterine region of interest (ROI) for each individual; constructing a second training set based on the multiplanar uterine ROI and the corresponding adenomyosis classification for each individual; constructing a deep learning model for adenomyosis classification; training the deep learning model based on the second training set to obtain an adenomyosis classification model; inputting the multiplanar MRI images of the individual to be classified into the trained segmentation models to obtain the multiplanar uterine ROI for the individual to be classified; and inputting the multiplanar uterine ROI of the individual to be classified into the adenomyosis classification model to obtain the adenomyosis classification for the individual to be classified. This achieves accurate and efficient adenomyosis classification.

The present invention relates to methods of imaging adenomyosis using the radiopharmaceutical agent 99mTc-maraciclatide. The technetium-99m radiopharmaceutical is suitably prepared from a non-radioactive kit containing the RGD peptide maraciclatide. Also described are methods of diagnosis, therapy selection and therapy monitoring of adenomyosis using the agent. The invention also includes the use of the kit and / or gamma camera or gamma detector in the methods of the invention.

The present invention relates to new uses and methods of treatment. More specifically, the invention relates to new uses of histone deacetylase inhibitors (HDACI) such as valproic acid (VPA), for enhancing in vitro fertilization (IVF) in patients suffering with adenomyosis associated infertility.